| Cat. No. |
Product Name |
Information |
| PC-Ab1035 |
Odronextamab
|
Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb), binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity independent of T-cell receptor recognition. Odronextamab has demonstrated preliminary efficacy in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).. |
| PC-Ab1034 |
Glofitamab
|
Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells a CD20/CD3 antibody (comprising two Fab regions for CD20 and one Fab region for CD3). Glofitamab redirects T cells to engage and eliminate malignant B cells.. |
| PC-Ab1033 |
Bemarituzumab
|
Bemarituzumab (FPA144) is a humanized monoclonal IgG1 antibody against fibroblast growth factor receptor 2b (FGFR2b, FGFR2IIIb), selectively binds to FGFR2b, inhibits ligand binding and mediates antibody-dependent cell-mediated cytotoxicity, recruits natural killer immune cells into the tumor microenvironment to kill the tumor cell in ADCC manner.. |
| PC-Ab1032 |
Oleclumab
|
Oleclumab (MEDI 9447) is a human IgG1 lambda mAb with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. |
| PC-Ab1031 |
Pembrolizumab
|
Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAF (V600) mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. . |
| PC-Ab1030 |
TGN1412
|
TGN1412 is a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. TGN1412 binds to the laterally exposed C′D loop of CD28 and demonstrated its therapeutic potential for use in autoimmune disease, led to a massive and uncontrolled release of proinflammatory cytokines (cytokine storm) during clinical phase I trials.. |
| PC-Ab1029 |
Daclizumab
|
Daclizuma binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). functions as an IL-2 receptor antagonist. Daclizuma specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.. |
| PC-Ab1028 |
Relatlimab
|
Relatlimab (BMS-986016) is a human IgG4 anti-LAG3 blocking mAb. Combination of LAG-3 with the immunomodulatory drug (IMiD) lenalidomide significantly increased IL-2 production by T cells and antibody-dependent cytotoxicity (ADCC) mediated by NK cells. These datas provide new insights into the potential anti-leukemic effects. |
| PC-Ab1027 |
Naptumomab
|
Naptumomab is a fusion protein containing the Fab-fragment of an antibody that targets the tumor-associated 5T4 antigen. Naptumomab activates T lymphocytes and targets them to the 5T4-expressing tumors, resulting in massive effector lymphocyte infiltration into the tumor and tumor cell killing. 5T4 (trophoblast glycoprotein, TPBG) is a transmembrane tumor antigen expressed on more than 90% of primary renal cell carcinomas (RCC) and a wide range of human carcinomas but not on most somatic adult t |
| PC-Ab1026 |
Urelumab
|
Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic, enhances NK-cell activation increasing CD25 expression and IFNɣ production, but not in vitro ADCC. Urelumab enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab.. |
| PC-Ab1025 |
Urelumab
|
Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic, enhances NK-cell activation increasing CD25 expression and IFNɣ production, but not in vitro ADCC. Urelumab enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab.. |
| PC-Ab1024 |
Cetuximab
|
Cetuximab binds specifically to the extracellular domain of the human EGFR, and down-regulates constitutively activated EGFR vIII on the cell surface. It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer. Cetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination th |
